Nkarta(US:NKTX)2025-05-14 20:14Financial Performance - Nkarta reported a net loss of $32.0 million, or $0.43 per share, for Q1 2025, compared to a net loss of $29.5 million, or $0.58 per share, in Q1 2024[11][25]. - Total operating expenses for Q1 2025 were $36.6 million, compared to $32.8 million in Q1 2024[10][25]. - Non-cash stock-based compensation included in R&D and G&A expenses for Q1 2025 was $1.1 million and $1.7 million, respectively[10][11]. Research and Development - Research and development (R&D) expenses for Q1 2025 were $24.2 million, while general and administrative (G&A) expenses were $12.4 million, which included $5.1 million in restructuring expenses[10][25]. - The Ntrust-1 clinical trial for NKX019 has expanded to include patients with primary membranous nephropathy, addressing unmet needs in this area[5][10]. - Preliminary clinical data from the Ntrust-1 and Ntrust-2 trials is anticipated in the second half of 2025[7][10]. - The company continues to enroll patients in the Ntrust-2 trial for systemic sclerosis and other autoimmune diseases[10][14]. Cash and Assets - Nkarta had a cash balance of $351.9 million as of March 31, 2025, expected to fund operations into 2029[6][12]. - Nkarta's total assets decreased from $501.2 million as of December 31, 2024, to $470.6 million as of March 31, 2025[27]. Restructuring Efforts - The company implemented a restructuring plan affecting 34% of its workforce to extend its cash runway by over one year[10][11].